UB Paderborn / Katalog / Suche / in CDI

Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study

BMC cancer, 2017-05, Vol.17 (1), p.332-332, Article 332

2017

Volltextzugriff (PDF)

Metastatic basal cell carcinoma: Prognosis dependent on anatomic site and spread of disease

European journal of cancer (1990), 2014-03, Vol.50 (4), p.774-783

2014

Volltextzugriff (PDF)

Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC

Journal of the American Academy of Dermatology, 2015-06, Vol.72 (6), p.1021-1026.e8

2015

Volltextzugriff (PDF)

A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma

Journal of the American Academy of Dermatology, 2015-07, Vol.73 (1), p.99-105.e1

2015

Volltextzugriff (PDF)

Randomized, Placebo-Controlled Phase II Study of Vandetanib Plus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2007-09, Vol.25 (27), p.4270-4277

2007

Volltextzugriff (PDF)

Correction to: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study

BMC cancer, 2019-04, Vol.19 (1), p.366-366, Article 366

2019

Volltextzugriff (PDF)

777 Initial results from an open-label phase 1b/2 study of RP1 oncolytic immunotherapy in solid organ and hematopoietic cell transplant recipients with advanced cutaneous malignancies (ARTACUS)

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A874-A874

2023

Volltextzugriff (PDF)

705 Biodistribution and shedding analysis following RP1 oncolytic immunotherapy dosing in patients from the IGNYTE clinical trial

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A800-A800

2023

Volltextzugriff (PDF)

Clinical “cytokine storm” as revealed by monocyte intracellular flow cytometry: correlation of tumor necrosis factor α with severe gut graft-versus-host disease

Clinical gastroenterology and hepatology, 2004-03, Vol.2 (3), p.237-245

2004

Volltextzugriff (PDF)

RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma

Future oncology (London, England), 2019-06, Vol.15 (16), p.1811-1822

2019

Volltextzugriff (PDF)

Abstract 1481: DAY101, a potent pan-RAF inhibitor with activity in preclinical models harboring MAPK pathway alterations beyond BRAF V600E mutation

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1481-1481

2021

Volltextzugriff (PDF)

Risk of cutaneous squamous cell carcinoma after treatment of basal cell carcinoma with vismodegib

Journal of the American Academy of Dermatology, 2017-10, Vol.77 (4), p.713-718

2017

Volltextzugriff (PDF)

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

The New England journal of medicine, 2011-06, Vol.364 (26), p.2507-2516

2011

Volltextzugriff (PDF)

Regulation of the Human hsp70 Promoter by p53

Science (American Association for the Advancement of Science), 1993-01, Vol.259 (5091), p.84-87

1993

Volltextzugriff (PDF)

Phase 1/2 study investigating safety, tolerability, pharmacokinetics, and preliminary antitumor activity of anti-PD-L1 monoclonal antibody bgb-A333 alone and in combination with anti-PD-1 monoclonal antibody tislelizumab in patients with advanced solid tumors

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.TPS3113-TPS3113

2018

Volltextzugriff (PDF)

Initial efficacy and safety of RP1 + nivolumab in patients with anti–PD-1–failed melanoma from the ongoing phase 1/2 IGNYTE study

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.9509-9509

2023

Volltextzugriff (PDF)

Efficient transfer of PSA and PSMA cDNAs into DCs generates antibody and T cell antitumor responses in vivo

Cancer gene therapy, 2005-06, Vol.12 (6), p.540-551

2005

Volltextzugriff (PDF)

Abstract CT084: Long-term exposure (LTE) to Tislelizumab, an investigational anti-PD-1 antibody, in a first-in-human Phase I study

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.CT084-CT084

2019

Volltextzugriff (PDF)

A phase 3, randomized, open-label, multicenter study to compare the efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.TPS3110-TPS3110

2018

Volltextzugriff (PDF)

The incidence of metastatic basal cell carcinoma (mBCC) in Denmark, 1997–2010

EJD. European journal of dermatology, 2015-09, Vol.25 (5), p.463-468

2015

Volltextzugriff (PDF)

Resistances to vismodegibs in a French case series of 207 patients with locally advanced basal cell carcinoma

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.9562-9562

2016

Volltextzugriff (PDF)

Metastatic basal cell carcinoma: Differences in survival by site of spread

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.8585-8585

2012

Volltextzugriff (PDF)

Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: Final update (30-month) of the pivotal ERIVANCE BCC study

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.9013-9013

2014

Volltextzugriff (PDF)

Vismodegib for advanced basal cell carcinoma: Duration of response after vismodegib discontinuation and response to vismodegib retreatment upon disease progression

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.9081-9081

2014

Volltextzugriff (PDF)

Vismodegib in the treatment of patients with metastatic basal cell carcinoma (mBCC) and distant metastases: Survival in the pivotal phase II and phase I studies

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.9012-9012

2014

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study

Metastatic basal cell carcinoma: Prognosis dependent on anatomic site and spread of disease

Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC

A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma

Randomized, Placebo-Controlled Phase II Study of Vandetanib Plus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer

Correction to: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study

777 Initial results from an open-label phase 1b/2 study of RP1 oncolytic immunotherapy in solid organ and hematopoietic cell transplant recipients with advanced cutaneous malignancies (ARTACUS)

705 Biodistribution and shedding analysis following RP1 oncolytic immunotherapy dosing in patients from the IGNYTE clinical trial

Clinical “cytokine storm” as revealed by monocyte intracellular flow cytometry: correlation of tumor necrosis factor α with severe gut graft-versus-host disease

RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma

Abstract 1481: DAY101, a potent pan-RAF inhibitor with activity in preclinical models harboring MAPK pathway alterations beyond BRAF V600E mutation

Risk of cutaneous squamous cell carcinoma after treatment of basal cell carcinoma with vismodegib

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

Regulation of the Human hsp70 Promoter by p53

Phase 1/2 study investigating safety, tolerability, pharmacokinetics, and preliminary antitumor activity of anti-PD-L1 monoclonal antibody bgb-A333 alone and in combination with anti-PD-1 monoclonal antibody tislelizumab in patients with advanced solid tumors

Initial efficacy and safety of RP1 + nivolumab in patients with anti–PD-1–failed melanoma from the ongoing phase 1/2 IGNYTE study

Efficient transfer of PSA and PSMA cDNAs into DCs generates antibody and T cell antitumor responses in vivo

Abstract CT084: Long-term exposure (LTE) to Tislelizumab, an investigational anti-PD-1 antibody, in a first-in-human Phase I study

A phase 3, randomized, open-label, multicenter study to compare the efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma

The incidence of metastatic basal cell carcinoma (mBCC) in Denmark, 1997–2010

Resistances to vismodegibs in a French case series of 207 patients with locally advanced basal cell carcinoma

Metastatic basal cell carcinoma: Differences in survival by site of spread

Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: Final update (30-month) of the pivotal ERIVANCE BCC study

Vismodegib for advanced basal cell carcinoma: Duration of response after vismodegib discontinuation and response to vismodegib retreatment upon disease progression

Vismodegib in the treatment of patients with metastatic basal cell carcinoma (mBCC) and distant metastases: Survival in the pivotal phase II and phase I studies

Suchergebnisse filtern